Faraday Pharmaceuticals, Inc.
Faraday Pharmaceuticals® is a clinical-stage biopharmaceutical company focused on preventing heart failure by reducing myocardial damage in acute STEMI. The company’s lead drug candidate, FDY-5301, is in a pivotal Phase 3 trial (Iocyte AMI-3) assessing its safety and efficacy in reducing cardiovascular death and heart failure in STEMI patients undergoing primary percutaneous intervention. FDY-5301 is an elemental reducing agent containing sodium iodide covered by method of use patent protection in major markets worldwide. FDY-5301 functions as a catalytic neutralizer of hydrogen peroxide, a prominent reactive oxygen species implicated in the ischemia reperfusion injury cascade leading to cardiomyocyte death, and also acts as an immunomodulating agent.
Additional Info
We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth!
NoACC.24 Learning Pathways? (select all that apply)
Heart Failure and Cardiomyopathies, Interventional and Structural Cardiology, Ischemic Heart DiseaseFirst time Exhibitor?
Yes